Literature DB >> 32861817

NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.

William A Hall1, Eric Paulson2, Brian J Davis3, Daniel E Spratt4, Todd M Morgan5, David Dearnaley6, Alison C Tree6, Jason A Efstathiou7, Mukesh Harisinghani8, Ashesh B Jani9, Mark K Buyyounouski10, Thomas M Pisansky3, Phuoc T Tran11, R Jeffrey Karnes12, Ronald C Chen13, Fabio L Cury14, Jeff M Michalski15, Seth A Rosenthal16, Bridget F Koontz17, Anthony C Wong18, Paul L Nguyen19, Thomas A Hope20, Felix Feng18, Howard M Sandler21, Colleen A F Lawton2.   

Abstract

PURPOSE: In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing nodal recurrence patterns. The objective of this study is to provide an updated prostate pelvic nodal consensus atlas. METHODS AND MATERIALS: A literature review was performed abstracting data on nodal recurrence patterns. Data were presented to a panel of international experts, including radiation oncologists, radiologists, and urologists. After data review, participants contoured nodal CTVs on 3 cases: postoperative, intact node positive, and intact node negative. Radiation oncologist contours were analyzed qualitatively using count maps, which provided a visual assessment of controversial regions, and quantitatively analyzed using Sorensen-Dice similarity coefficients and Hausdorff distances compared with the 2009 RTOG atlas. Diagnostic radiologists generated a reference table outlining considerations for determining clinical node positivity.
RESULTS: Eighteen radiation oncologists' contours (54 CTVs) were included. Two urologists' volumes were examined in a separate analysis. The mean CTV for the postoperative case was 302 cm3, intact node positive case was 409 cm3, and intact node negative case was 342 cm3. Compared with the original RTOG consensus, the mean Sorensen-Dice similarity coefficient for the postoperative case was 0.63 (standard deviation [SD] 0.13), the intact node positive case was 0.68 (SD 0.13), and the intact node negative case was 0.66 (SD 0.18). The mean Hausdorff distance (in cm) for the postoperative case was 0.24 (SD 0.13), the intact node positive case was 0.23 (SD 0.09), and intact node negative case was 0.33 (SD 0.24). Four regions of CTV controversy were identified, and consensus for each of these areas was reached.
CONCLUSIONS: Discordance with the 2009 RTOG consensus atlas was seen in a group of experienced NRG Oncology and international genitourinary radiation oncologists. To address areas of variability and account for new data, an updated NRG Oncology consensus contour atlas was developed.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32861817      PMCID: PMC7736505          DOI: 10.1016/j.ijrobp.2020.08.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer.

Authors:  Simon K B Spohn; Viktoria Birkenmaier; Juri Ruf; Michael Mix; August Sigle; Erik Haehl; Sonja Adebahr; Tanja Sprave; Eleni Gkika; Alexander Rühle; Nils H Nicolay; Simon Kirste; Anca L Grosu; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

2.  The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy.

Authors:  Irina Filimonova; Daniela Schmidt; Sina Mansoorian; Thomas Weissmann; Hadi Siavooshhaghighi; Alexander Cavallaro; Torsten Kuwert; Christoph Bert; Benjamin Frey; Luitpold Valentin Distel; Sebastian Lettmaier; Rainer Fietkau; Florian Putz
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

3.  Development of explanatory movies for the delineation of new organs at risk in neuro-oncology.

Authors:  Dario Di Perri; David Hofstede; Alida Postma; Catharina M L Zegers; Lieke In't Ven; Frank Hoebers; Wouter van Elmpt; Lindsey Verheesen; Hilde Beurskens; Esther G C Troost; Inge Compter; Danielle B P Eekers
Journal:  Clin Transl Radiat Oncol       Date:  2022-02-15

4.  Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.

Authors:  Darren M C Poon; Bin Yang; Hui Geng; Oi Lei Wong; Sin Ting Chiu; Kin Yin Cheung; Siu Ki Yu; George Chiu; Jing Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-24       Impact factor: 4.553

Review 5.  Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer.

Authors:  Rohann J M Correa; Andrew Loblaw
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

6.  A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.

Authors:  Darren M C Poon; Jing Yuan; Bin Yang; Oi-Lei Wong; Sin-Ting Chiu; George Chiu; Kin-Yin Cheung; Siu-Ki Yu; Raymond W H Yung
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

7.  PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation.

Authors:  Julia Murray; Clare Cruickshank; Thomas Bird; Philip Bell; John Braun; Dave Chuter; Miguel Reis Ferreira; Clare Griffin; Shama Hassan; Nabil Hujairi; Alan Melcher; Elizabeth Miles; Olivia Naismith; Miguel Panades; Lara Philipps; Alison Reid; Jan Rekowski; Pete Sankey; John Staffurth; Isabel Syndikus; Alison Tree; Anna Wilkins; Emma Hall
Journal:  Clin Transl Radiat Oncol       Date:  2022-09-24

Review 8.  Practical considerations for prostate hypofractionation in the developing world.

Authors:  Michael Yan; Andre G Gouveia; Fabio L Cury; Nikitha Moideen; Vanessa F Bratti; Horacio Patrocinio; Alejandro Berlin; Lucas C Mendez; Fabio Y Moraes
Journal:  Nat Rev Urol       Date:  2021-08-13       Impact factor: 14.432

9.  Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand.

Authors:  David I Pryor; Jarad M Martin; Jeremy L Millar; Heather Day; Wee Loon Ong; Marketa Skala; Liesel M FitzGerald; Benjamin Hindson; Braden Higgs; Michael E O'Callaghan; Farhan Syed; Amy J Hayden; Sandra L Turner; Nathan Papa
Journal:  JAMA Netw Open       Date:  2021-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.